Literature DB >> 33627128

Inflammasome activation controlled by the interplay between post-translational modifications: emerging drug target opportunities.

Zhu Liang1,2, Andreas Damianou3, Elena Di Daniel3,4, Benedikt M Kessler5,6.   

Abstract

Controlling the activation of the NLRP3 inflammasome by post-translational modifications (PTMs) of critical protein subunits has emerged as a key determinant in inflammatory processes as well as in pathophysiology. In this review, we put into context the kinases, ubiquitin processing and other PTM enzymes that modify NLRP3, ASC/PYCARD and caspase-1, leading to inflammasome regulation, activation and signal termination. Potential target therapeutic entry points for a number of inflammatory diseases focussed on PTM enzyme readers, writers and erasers, leading to the regulation of inflammasome function, are discussed. Video Abstract.

Entities:  

Keywords:  Drug targets; NLRP3 inflammasome; Post-translational modifications; Protein interaction; Signalling

Mesh：

Substances：

Year:  2021        PMID： 33627128      PMCID： PMC7905589          DOI： 10.1186/s12964-020-00688-6

Source DB:  PubMed          Journal:  Cell Commun Signal        ISSN： 1478-811X            Impact factor:   5.712


  67 in total

1.  R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.

Authors:  Sylvia Braselmann; Vanessa Taylor; Haoran Zhao; Su Wang; Catherine Sylvain; Muhammad Baluom; Kunbin Qu; Ellen Herlaar; Angela Lau; Chi Young; Brian R Wong; Scott Lovell; Thomas Sun; Gary Park; Ankush Argade; Stipo Jurcevic; Polly Pine; Rajinder Singh; Elliott B Grossbard; Donald G Payan; Esteban S Masuda
Journal:  J Pharmacol Exp Ther       Date:  2006-08-31       Impact factor: 4.030

2.  NLRP3 inhibitors stoke anti-inflammatory ambitions.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2019-06       Impact factor: 84.694

3.  Cullin1 binds and promotes NLRP3 ubiquitination to repress systematic inflammasome activation.

Authors:  Pin Wan; Qi Zhang; Weiyong Liu; Yaling Jia; Sha Ai; Tianci Wang; Wenbiao Wang; Pan Pan; Ge Yang; Qi Xiang; Siyu Huang; Qingyu Yang; Wei Zhang; Fang Liu; Qiuping Tan; Wen Zhang; Kailang Wu; Yingle Liu; Jianguo Wu
Journal:  FASEB J       Date:  2019-01-17       Impact factor: 5.191

4.  Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome.

Authors:  Yiqing Yan; Wei Jiang; Lei Liu; Xiaqiong Wang; Chen Ding; Zhigang Tian; Rongbin Zhou
Journal:  Cell       Date:  2015-01-15       Impact factor: 41.582

5.  NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder.

Authors:  Laetitia Agostini; Fabio Martinon; Kimberly Burns; Michael F McDermott; Philip N Hawkins; Jürg Tschopp
Journal:  Immunity       Date:  2004-03       Impact factor: 31.745

6.  A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles.

Authors:  Sebastian A Wagner; Petra Beli; Brian T Weinert; Michael L Nielsen; Jürgen Cox; Matthias Mann; Chunaram Choudhary
Journal:  Mol Cell Proteomics       Date:  2011-09-01       Impact factor: 5.911

7.  IKKα negatively regulates ASC-dependent inflammasome activation.

Authors:  Bradley N Martin; Chenhui Wang; Jami Willette-Brown; Tomasz Herjan; Muhammet F Gulen; Hao Zhou; Katarzyna Bulek; Luigi Franchi; Takashi Sato; Emad S Alnemri; Goutham Narla; Xiao-Ping Zhong; James Thomas; Dennis Klinman; Katherine A Fitzgerald; Michael Karin; Gabriel Nuñez; George Dubyak; Yinling Hu; Xiaoxia Li
Journal:  Nat Commun       Date:  2014-09-30       Impact factor: 14.919

8.  The deubiquitinating enzyme, ubiquitin-specific peptidase 50, regulates inflammasome activation by targeting the ASC adaptor protein.

Authors:  Jae Young Lee; Dongyeob Seo; Jiyeon You; Sehee Chung; Jin Seok Park; Ji-Hyung Lee; Su Myung Jung; Youn Sook Lee; Seok Hee Park
Journal:  FEBS Lett       Date:  2017-01-29       Impact factor: 4.124

9.  USP7 and USP47 deubiquitinases regulate NLRP3 inflammasome activation.

Authors:  Pablo Palazón-Riquelme; Jonathan D Worboys; Jack Green; Ana Valera; Fatima Martín-Sánchez; Carolina Pellegrini; David Brough; Gloria López-Castejón
Journal:  EMBO Rep       Date:  2018-09-11       Impact factor: 8.807

10.  Src-family kinase-Cbl axis negatively regulates NLRP3 inflammasome activation.

Authors:  I-Che Chung; Sheng-Ning Yuan; Chun-Nan OuYang; Hsin-Chung Lin; Kuo-Yang Huang; Yu-Jen Chen; An-Ko Chung; Ching-Liang Chu; David M Ojcius; Yu-Sun Chang; Lih-Chyang Chen
Journal:  Cell Death Dis       Date:  2018-10-31       Impact factor: 8.469
View more
  10 in total

Review 1.  Role of Pyroptosis, a Pro-inflammatory Programmed Cell Death, in Epilepsy.

Authors:  Rabi Atabaki; Hossein Khaleghzadeh-Ahangar; Nardana Esmaeili; Parvaneh Mohseni-Moghaddam
Journal:  Cell Mol Neurobiol       Date:  2022-07-14       Impact factor: 4.231

Review 2.  NLRP3 Inflammasome in Vascular Disease: A Recurrent Villain to Combat Pharmacologically.

Authors:  Ainara González-Moro; Inés Valencia; Licia Shamoon; Carlos Félix Sánchez-Ferrer; Concepción Peiró; Fernando de la Cuesta
Journal:  Antioxidants (Basel)       Date:  2022-01-29

Review 3.  The NLRP3 Inflammasome: Relevance in Solid Organ Transplantation.

Authors:  Ryan M Burke; Bethany L Dale; Shamik Dholakia
Journal:  Int J Mol Sci       Date:  2021-10-03       Impact factor: 5.923

4.  TBK1 and IKKε act like an OFF switch to limit NLRP3 inflammasome pathway activation.

Authors:  Fabian A Fischer; Linda F M Mies; Sohaib Nizami; Eirini Pantazi; Sara Danielli; Benjamin Demarco; Michael Ohlmeyer; Michelle Sue Jann Lee; Cevayir Coban; Jonathan C Kagan; Elena Di Daniel; Jelena S Bezbradica
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-21       Impact factor: 11.205

5.  Mitochondrial Generated Redox Stress Differently Affects the Endoplasmic Reticulum of Circulating Lymphocytes and Monocytes in Treatment-Naïve Hodgkin's Lymphoma.

Authors:  Cecilia Marini; Vanessa Cossu; Matteo Bauckneht; Sonia Carta; Francesco Lanfranchi; Francesca D'Amico; Silvia Ravera; Anna Maria Orengo; Chiara Ghiggi; Filippo Ballerini; Paolo Durando; Sabrina Chiesa; Alberto Miceli; Maria Isabella Donegani; Silvia Morbelli; Silvia Bruno; Gianmario Sambuceti
Journal:  Antioxidants (Basel)       Date:  2022-04-11

Review 6.  Posttranslational Regulation of Inflammasomes, Its Potential as Biomarkers and in the Identification of Novel Drugs Targets.

Authors:  Sambit K Nanda; Stefan Vollmer; Ana B Perez-Oliva
Journal:  Front Cell Dev Biol       Date:  2022-06-21

7.  Antistroke Network Pharmacological Prediction of Xiaoshuan Tongluo Recipe Based on Drug-Target Interaction Based on Deep Learning.

Authors:  Yongfu Zhou
Journal:  Comput Math Methods Med       Date:  2022-08-02       Impact factor: 2.809

Review 8.  Inflammasomes in Alveolar Bone Loss.

Authors:  Yang Li; Junqi Ling; Qianzhou Jiang
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

9.  Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor.

Authors:  Simone Gastaldi; Valentina Boscaro; Eleonora Gianquinto; Christina F Sandall; Marta Giorgis; Elisabetta Marini; Federica Blua; Margherita Gallicchio; Francesca Spyrakis; Justin A MacDonald; Massimo Bertinaria
Journal:  Molecules       Date:  2021-06-29       Impact factor: 4.411

Review 10.  Modulatory Properties of Food and Nutraceutical Components Targeting NLRP3 Inflammasome Activation.

Authors:  Mattia Spano; Giacomo Di Matteo; Cinzia Ingallina; Donatella Ambroselli; Simone Carradori; Marialucia Gallorini; Anna Maria Giusti; Andrea Salvo; Michela Grosso; Luisa Mannina
Journal:  Nutrients       Date:  2022-01-23       Impact factor: 5.717
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.